Treatment of Allergic Eosinophilic Asthma through Engineered IL-5-Anchored Chimeric Antigen Receptor T Cells

Researchers engineered a cytokine-anchored CAR T cell system using a chimeric IL-5-CD28-CD3ζ receptor to trigger T-cell-mediated killing of eosinophils that were elevated during severe asthma attacks.